SCYNEXIS develops fungerps, a novel class of triterpenoid antifungal agents distinct from traditional glucan synthase inhibitors. The company has licensing partnerships with GlaxoSmithKline, Merck Sharp & Dohme, Hansoh, R-Pharm, and Cypralis for development and commercialization of ibrexafungerp globally.
Cyborg Score Rationale
Revenue declined dramatically to $3.7M in 2024 from higher prior year levels, with negative operating income of -$37.1M. Despite strong partnership relationships and a novel drug class, the company faces significant commercialization challenges and minimal current revenue generation.
Top Insights
Ibrexafungerp represents a novel antifungal class with unique mechanism offering advantage in treating drug-resistant infections.
Wall Street consensus is bullish with 7 buy ratings, average 12-month price target of $30.29 (314% upside), but stock trades significantly below target.
GSK acquisition in 2023 provided significant resources and expertise to advance global development and commercialization.
Company operates with only 28 employees, suggesting outsourced R&D and reliance on external partnerships.
Named Competitors
Conventional Antifungals — Traditional azoles and polyenes for fungal infections
SCY-247 — Second-generation IV/oral triterpenoid antifungal in development
Emerging Antifungal Programs — Various preclinical antifungal candidates
Recent Developments
(Feb 2025) Participation in Guggenheim 6th Annual Biotechnology Conference in New York
(2024) Significant revenue decline; shift to partnership-driven commercialization model
(2023) GSK acquisition providing global development and commercialization support
Open the full interactive SCYNEXIS, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.